News and Announcements
Genesis Algae Moves Closer to First Sales
- Published April 17, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Genesis Algae has moved closer to first sales in the human health market. The first batch of Chlorella algae has now been dried into powder form and packaged, ready for sales over the coming weeks.
KEY TAKEAWAYS:
- Genesis has recently returned from the largest natural health expo in the world- Expo West in Los Angeles.
- The department of Trade and Investment Queensland sponsored Genesis attendance at this event, coordinating introductions with buyers and retailers.
- Many potential customers both in Australia and the USA have been identified overall being a success.
- The company has constructed its first commercial facility in Bowen and will expand the current pond system during 2017 to meet demand.
- Genesis is currently undertaking a $500k capital raising which is now 60% subscribed.
Genesis agreed to terms of purchase of a 20-hectare parcel of land adjacent to existing facility, providing all the land required to ramp up production over the next few years. Construction of new ponds will commence immediately and will progressively come on line over the coming months.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
